Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

13.5K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
13.5K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

8.2K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
8.2K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

2.3K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
2.3K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

7.4K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
7.4K
Detailed Structure and Function of Lymph Nodes01:23

Detailed Structure and Function of Lymph Nodes

3.6K
Lymph nodes are bean-shaped structures that cluster along the lymphatic vessels in the inguinal, axillary, and cervical regions. Each node is divided into compartments by a capsule that extends trabeculae inward.
From a histological perspective, lymph nodes can be split into two main areas: the superficial cortex and the deep medulla. The outer cortex is populated by dendritic cells, macrophages, and B lymphocytes, which are densely packed into follicles. When these B-lymphocytes are presented...
3.6K
Lymphatic Vessels and Lymph Transport01:16

Lymphatic Vessels and Lymph Transport

21.3K
Lymphatic vessels, known as lymphatics, are crucial in transporting lymph from peripheral tissues to our venous system. This process begins with lymph entering through tiny capillaries that branch through tissues. These capillaries have unique features such as larger diameters, thinner walls, and a distinctive one-way valve system formed by overlapping endothelial cells.
This one-way system allows fluids, solutes, and even pathogens to enter but prevents their return to the intercellular...
21.3K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026
Same author

Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty.

Journal of geriatric oncology·2026
Same author

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

JAMA oncology·2026
Same author

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.

Leukemia·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Nov 20, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.3K

El linfoma de Hodgkin clásico

Pauline Brice1, Eric de Kerviler2, Jonathan W Friedberg3

  • 1Department of Oncohaematology, Hôpital saint Louis APHP, Université Paris 7, Paris, France.

Lancet (London, England)
|January 25, 2021
PubMed
Resumen
Este resumen es generado por máquina.

El linfoma de Hodgkin clásico es un cáncer común, a menudo curable con quimioterapia. Sin embargo, algunos pacientes no se curan, y otros se enfrentan a efectos secundarios a largo plazo del tratamiento, que afectan a los años de vida.

Más Videos Relacionados

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.4K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.5K

Videos de Experimentos Relacionados

Last Updated: Nov 20, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.3K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.4K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.5K

Área de la Ciencia:

  • En el campo de la oncología
  • Hematología
  • Investigación del cáncer

Sus antecedentes:

  • El linfoma de Hodgkin clásico (LHC) es una malignidad hematológica frecuente.
  • La quimioterapia estándar de primera línea y la radioterapia ofrecen altas tasas de curación para la LHC.
  • Los problemas no resueltos incluyen la resistencia al tratamiento y las toxicidades a largo plazo.

Objetivo del estudio:

  • Revisar los retos actuales en el tratamiento clásico del linfoma de Hodgkin.
  • Discutir el impacto de los efectos tóxicos tardíos en la supervivencia del paciente.
  • Para resaltar los avances recientes, incluida la inmunoterapia en entornos de recaída.

Principales métodos:

  • Revisión de la literatura actual sobre el linfoma de Hodgkin clásico.
  • Análisis de los resultados del tratamiento y toxicidad tardía.
  • Examen de las estrategias terapéuticas emergentes.

Principales resultados:

  • A pesar de las altas tasas de curación, un subconjunto de pacientes sigue siendo refractario al tratamiento de primera línea.
  • La mortalidad prematura en pacientes curados a menudo se atribuye a toxicidades relacionadas con el tratamiento tardío.
  • La inmunoterapia ha surgido como una opción significativa, particularmente para la enfermedad recidivante o refractaria.

Conclusiones:

  • Abordar la resistencia al tratamiento y mitigar las toxicidades a largo plazo es fundamental para mejorar los resultados en el linfoma de Hodgkin clásico.
  • El panorama evolutivo del tratamiento, incluida la inmunoterapia, ofrece nuevas esperanzas para los pacientes con recaída de la enfermedad.
  • La optimización de la terapia para equilibrar las tasas de curación con la calidad de vida a largo plazo sigue siendo un objetivo clave.